Happy Monday! Speculative fervor is heating up again, with legendary short-seller Jim Chanos comparing today’s market to the extreme conditions of 2021. Find out why he’s sounding the alarm — and what it could mean for investors navigating these volatile times. Also, check out these stocks that are hardly getting much attention.

—Josh Enomoto

Plus, if you’re looking to invest in a new approach against psoriasis, check out today’s sponsor.

MARKET RECAP

Last Week: Stocks declined Friday as inflation concerns weighed on sentiment, with the S&P 500 slipping 0.6% and the Dow falling 0.9%. Bond yields edged higher as markets reassessed Fed rate cut expectations, while consumer sentiment dropped to a six-month low, reflecting renewed inflation worries.

On Our Radar: After last week’s wild ride, analysts will next turn to Wednesday’s consumer price index. On the earnings front, McDonald’s Q4 results will likely dominate headlines, especially following the late-October E. coli outbreak.

TOP STORY

Legendary Short Seller Jim Chanos Warns Of Market Speculation Reaching Historic Extremes: 'Wall Street Has A Printing Press Too'

Market veteran Jim Chanos is sounding the alarm on speculative excess, warning that Wall Street is edging closer to the frenzy seen during the pandemic era.

See what this could mean for stocks — and how investors can navigate the risks ahead.

SPONSORED CONTENT

Soligenix Targets Psoriasis With New Therapy

The skin is the largest organ in the human body. Its softness allows for movement and flexibility, yet it is also durable enough to resist breaking or tearing. As one of the body’s more versatile organs, it serves multiple functions, such as being the first line of defense against bacteria and other organisms. However, the skin has another vital role as an indicator of good health; if someone is sick, it often shows in their skin.

Soligenix, Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases and areas of unmet medical need, is utilizing its pharmaceutical expertise to tackle psoriasis, an autoimmune skin condition that causes itchiness and discomfort. Discover how Soligenix, Inc. is advancing treatments for psoriasis and improving skin health!

This is a paid ad. Please see 17b disclosure here for more information.

FIVE ZINGERS

Bold Moves: Cathie Wood's Ark Invest made several big transactions involving a number of prominent companies. Read what's on the entrepreneur's buy list.

Legal Woes: A progressive think tank has urged the Justice Department to scrutinize the legality of the meme coin TRUMP. Learn the details of what's triggering this request.

Under Water: Robert F. Kennedy Jr. recently revealed that he carries up to $1.2 million in credit card debt. Discover the broader implications behind this surprising revelation.

Change Up: Athletic apparel giant Nike has decided to return to Super Bowl advertising after a 27-year hiatus. Learn about the reason that sparked the move.

The Breakdown: Last week was an eventful one for the market, with the January jobs report broadcasting mixed economic signals. Here are the stocks attracting interest at this juncture.

SPECIAL OFFER

5 Stocks Investors Secrety Monitor But Don’t Talk About Yet

Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention.

Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.

The Trade Desk (TTD): The digital advertising company saw strong interest from readers during the week, which comes ahead of fourth-quarter financial results on Feb. 12. Analysts expect the company to report quarterly revenue of $758.9 million, up from $605.8 million in last year's fourth quarter.

Analysts expect the company to report earnings per share of 56 cents for the fourth quarter, up from 41 cents per share in last year's fourth quarter. The company has beaten analyst estimates for revenue in more than 10 straight quarters and beaten estimates for earnings per share in three straight quarters and eight of the last 10 quarters overall.

To keep reading, and get the other four Whisper Index stocks, sign up for Benzinga Edge here.

SPECIAL OFFER

Get Ready For The Market’s Next Big Moves - 5 New Stock Recommendations Every Week

Join Chris Capre on February 12 at 6 PM ET as he breaks down how to trade through rising tariffs, inflation uncertainty and global instability. Understand how major economic shifts are impacting the markets—and how you can turn volatility into profit. Reserve your seat now.

BEFORE YOU GO

Were you forwarded this email? Click here to subscribe.

And be sure to check out our other newsletters:

Future Finance: Where fintech, crypto, and the future of finance collide. Future Finance is a perfect lunch read packed with quick bites for industry enthusiasts. Subscribe here.

Cannabis Daily: A must-read daily briefing for cannabis investors, operators, and enthusiasts. Join our list of industry veterans to jump start your morning. Subscribe here.

Real Estate Weekly: Ready to elevate your real estate game? This weekly newsletter provides actionable insights whether you are investing in REITs, owning property, or delving into the fast-growing world of fractional real estate. Subscribe here.

Advisor: Tailor-made for Financial Advisors, this weekly newsletter has industry-specific insights, analysis, and news. Subscribe here.

Tech Trends: Get the inside scoop on AI, the hottest gadgets, and mind-blowing tech trends. Subscribe here.